review of glp 1 IUPHAR – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target GLP-1 and the kidney: from

Lilly's currently approved injection, Zepbound, and Novo Nordisk's Wegovy have shown weight loss of roughly 15% to 20% in different trials, according to Reuters, while Lilly's oral obesity pill, Foundayo, has delivered about 11% weight loss

Continuous glucose monitoring systems: are they useful for evaluating glycemic control in children with hyperinsulinism

Neither tool is universally "better." The right choice depends on your needs

At the same time, limit sugary snacks (soda, candy, flavored yogurt, and fruit juice) and refined carbohydrates (white bread, pastries, and pasta), which can cause blood sugar spikes and press your pancreas to produce more insulin (12)

Some researchers interpret this as "the medication is not for me" rather than recognizing it as a timing problem specific to escalation